Literature DB >> 27200870

Long-Term Maintenance of Improvements in Patient-Reported Outcomes With Certolizumab Pegol in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Results of the Rapid-Axspa Study.

J Sieper1, A Kivitz2, A van Tubergen3, A Deodhar4, B Szegvari5, T Nurminen6, R Landewé7.   

Abstract

Entities:  

Year:  2014        PMID： 27200870     DOI： 10.1016/j.jval.2014.08.2643

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  3 in total

1.  Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial.

Authors:  Jessica A Walsh; Marina N Magrey; Xenofon Baraliakos; Kentaro Inui; Meng-Yu Weng; Ennio Lubrano; Désirée van der Heijde; Annelies Boonen; Lianne S Gensler; Vibeke Strand; Jürgen Braun; Theresa Hunter; Xiaoqi Li; Baojin Zhu; Luis León; David Marcelino Sandoval Calderon; Uta Kiltz
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-01-26       Impact factor: 5.178

Review 2.  Challenges of diagnosis and management of axial spondyloarthritis in North Africa and the Middle East: An expert consensus.

Authors:  Mohammed Hammoudeh; Sultana Abdulaziz; Hanan Alosaimi; Hanan Al-Rayes; Hussam Aldeen Sarakbi; Matouqa Baamer; Xenofon Baraliakos; Chafia Dahou Makhloufi; Nahid Janoudi; Khalid Shirazy; Joachim Sieper; Uppal Sukhbir
Journal:  J Int Med Res       Date:  2016-01-25       Impact factor: 1.671

Review 3.  Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy.

Authors:  Josefina Marin; María Laura Acosta Felquer; Enrique R Soriano
Journal:  Open Access Rheumatol       Date:  2018-05-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.